Lumora Acquired by ERBA Diagnostics Mannheim
News Sep 16, 2015
The acquisition will see Lumora’s molecular diagnostics technology for the clinical and industrial sectors merged with ERBA Diagnostics Mannheim’s existing businesses for in-vitro diagnostic testing across the world, covering a wide range of market segments. Financial details were not disclosed.
Lumora’s technology provides a strong addition to the ERBA Diagnostics Mannheim portfolio. Through the acquisition of the Lumora technology, ERBA Mannheim has been able to expand its portfolio to include molecular testing for hospital acquired infections and emerging market specific infectious diseases, such as HIV and respiratory diseases. Alongside the molecular testing, ERBA Diagnostics Mannheim will be able to further commercialise Lumora’s technologies such as RapidMag and BART. In addition, Lumora, has a number of ongoing commercial partnerships which will continue following the acquisition.
Mr. Suresh Vazirani, Chairman and Managing Director of ERBA Diagnostics Mannheim, said: “We are very pleased to have concluded this acquisition. Lumora has a strong portfolio of molecular technologies in growing areas which will complement our existing business. In addition, Lumora’s excellent commercial partnerships can be used to further expand ERBA Diagnostic Mannheim’ global business.”
Laurence Tisi, CEO of Lumora, said: “ERBA Diagnostics Mannheim is an excellent home for Lumora’s technology. The company has a strong global presence and is well established in a number of key market segments. With the acquisition of Lumora, and its novel technology, ERBA Diagnostics Mannheim is now well placed to expand the utility of the technologies globally.
Hayden Jeffreys, Commercial Director at Lumora, said: “The successful conclusion of the acquisition by ERBA Diagnostics Mannheim shows the strength of Lumora’s technology. Not only is it ideal for specific markets such as hospital acquired infections and HIV testing, the technologies can also be applied to a wide range of existing clinical and industrial diagnostics.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE